Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.50 USD
Change Today -0.39 / -5.66%
Volume 99.8K
CCXI On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

chemocentryx inc (CCXI) Key Developments

ChemoCentryx, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

ChemoCentryx, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's loss from operations was $12,178,000 compared with $12,384,000 a year ago. Net loss was $12,078,000 or $0.28 per basic and diluted share compared with $12,261,000 or $0.28 per basic and diluted share a year ago. For the six months, the company's loss from operations was $24,287,000 compared with $24,056,000 a year ago. Net loss was $24,084,000 or $0.55 per basic and diluted share compared with $23,798,000 or $0.55 per basic and diluted share a year ago.

ChemoCentryx, Inc. Announces Board Changes

ChemoCentryx, Inc. announced that effective July 28, 2015, Thomas A. Edwards, retired partner of Latham & Watkins, LLP, has been appointed to the Company's Board of Directors. Mr. Edwards will serve as a Class III director until the 2017 annual stockholder's meeting. The Company also announced that effective as of the same date, Ira Klein, MD, MBA, FACP resigned from the Company's Board of Directors. Thomas Edwards has more than three decades of legal experience in the life sciences industry. Prior to his retirement from Latham & Watkins in 2014, Mr. Edwards supported dozens of biopharmaceutical companies in their general legal efforts, capital financings, acquisitions, partnerships and numerous other strategic business and legal initiatives.

ChemoCentryx, Inc. to Report Q2, 2015 Results on Aug 06, 2015

ChemoCentryx, Inc. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Aug 06, 2015

ChemoCentryx, Inc., Q2 2015 Earnings Call, Aug 06, 2015

ChemoCentryx, Inc., Q2 2015 Earnings Call, Aug 06, 2015

ChemoCentryx, Inc. Announces Positive Results from Chemocentryx Phase II Diabetic Nephropathy Trial with Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted At the 52nd ERA-EDTA Congress

ChemoCentryx, Inc. announced data presentations from two of its chemoattractant receptor programs, CCR2 and C5aR, at the 52ndEuropean Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress being held May 28 to 31 in London, UK. In a Late Breaking Clinical Trial presentation, positive 52-week data from the Company's Phase II clinical trial in patients with diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2, were presented by Professor Dick de Zeeuw, M.D., Ph.D., Chair of the Research Section of the Department of Clinical Pharmacy and Pharmacology at the University Medical Center in Groningen, The Netherlands. Professor de Zeeuw's oral presentation focused on the CCX140 Phase II study and its primary endpoint. As previously announced, top line data from the CCX140 Phase II trial in patients with diabetic nephropathy included the following results: the trial met its primary endpoint by demonstrating that treatment with 5 mg of CCX140 given orally once daily added to a standard of care regimen (SOC) of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor II blocker (ARB) treatment resulted in a statistically significant (p=0.0148) reduction in urinary albumin:creatinine ratio (UACR), beyond that achieved with SOC alone; the maximum treatment effect was reached at 12 weeks; in patients who received 5 mg CCX140 continuously for 52 weeks, a sustained reduction in albuminuria induced by CCX140 relative to SOC alone was observed over the full year; treatment with CCX140 showed improvements in the profile of the estimated glomerular filtration rate (eGFR), represented by an attenuation in the slope of annual decline in eGFR. The treatment group receiving 5 mg of CCX140 in addition to SOC showed an attenuated annual slope decline of 1.9 mL/min/1.73 m2, compared to SOC alone group, 3.4 mL/min/1.73 m2. These results represent a 44% annualized improvement in eGFR over SOC alone; in a pre-specified sub-population in the study, patients who were highly proteinuric (baseline albuminuria levels of 800mg/g creatinine and above), a 66% annualized relative improvement in eGFR slope over SOC alone was observed; CCX140 appeared to be well tolerated with a low overall dropout rate over the 52-week treatment period. Regarding another chemoattractant receptor inhibitor program at the Company, ChemoCentryx scientists and their collaborators will outline research in atypical Hemolytic Uremic Syndrome (aHUS) and the ability of CCX168, a C5aR inhibitor, to significantly reduce the formation of platelet micro-thrombi on an ex-vivo assay system of endothelial cells. These data will be presented in a poster session on May 30th. The inhibition of micro-thrombi was dose-dependent on CCX168 and, in side-by-side experiments, the anti-thrombotic effect of CCX168 were comparable to that of eculizumab, which is the first agent approved for aHUS. The Company is initiating a CCX168 Phase IIa proof-of-concept study in aHUS patients with end stage renal disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCXI:US $6.50 USD -0.39

CCXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CCXI.
View Industry Companies
 

Industry Analysis

CCXI

Industry Average

Valuation CCXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMOCENTRYX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.